Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing

I. Kishimoto, F. K. Hamra, D. L. Garbers

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Two natriuretic peptides, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), are found principally in the heart. In preliminary experiments with mouse kidney cells or slices, we found mouse BNP1-45 much more potent than ANP1-28 in causing elevations of cGMP (>50-fold). The guanylyl cyclase-A (GC-A) receptor has been suggested to represent the primary means by which both peptides signal. In cultured cells overexpressing GC-A, BNP and ANP were almost equivalent in potency, suggesting that a receptor unique for BNP exists in the kidney. However, in mice lacking the GC-A gene, neither BNP nor ANP significantly elevated cGMP in kidney slices. Phosphoramidon, a neutral endopeptidase inhibitor, shifted the apparent potency of ANP to values equivalent to that of BNP, suggesting these kidney cell/slices rapidly degrade ANP but not BNP. Mass spectroscopic analysis confirmed that ANP is rapidly cleaved at the first cysteine of the disulfide ring, whereas BNP is particularly stable to such cleavage. Other tissues (heart, aorta) failed to significantly degrade ANP or BNP, and therefore the kidney-specific degradation of ANP provides a mechanism for preferential regulation of kidney function by BNP independent of peripheral ANP concentration.

Original languageEnglish (US)
Pages (from-to)715-722
Number of pages8
JournalCanadian Journal of Physiology and Pharmacology
Volume79
Issue number8
DOIs
StatePublished - 2001

Fingerprint

Brain Natriuretic Peptide
Atrial Natriuretic Factor
Kidney
Neprilysin
Natriuretic Peptides
Protein Sorting Signals
Protease Inhibitors
Disulfides
Cysteine
Aorta
Cultured Cells

Keywords

  • Atrial natriuretic peptide
  • B-type natriuretic peptide
  • Guanylyl cyclase-A
  • Neutral endopeptidase

ASJC Scopus subject areas

  • Physiology
  • Pharmacology

Cite this

Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing. / Kishimoto, I.; Hamra, F. K.; Garbers, D. L.

In: Canadian Journal of Physiology and Pharmacology, Vol. 79, No. 8, 2001, p. 715-722.

Research output: Contribution to journalArticle

@article{1882c3427e194dc3b2fae4b664e946a8,
title = "Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing",
abstract = "Two natriuretic peptides, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), are found principally in the heart. In preliminary experiments with mouse kidney cells or slices, we found mouse BNP1-45 much more potent than ANP1-28 in causing elevations of cGMP (>50-fold). The guanylyl cyclase-A (GC-A) receptor has been suggested to represent the primary means by which both peptides signal. In cultured cells overexpressing GC-A, BNP and ANP were almost equivalent in potency, suggesting that a receptor unique for BNP exists in the kidney. However, in mice lacking the GC-A gene, neither BNP nor ANP significantly elevated cGMP in kidney slices. Phosphoramidon, a neutral endopeptidase inhibitor, shifted the apparent potency of ANP to values equivalent to that of BNP, suggesting these kidney cell/slices rapidly degrade ANP but not BNP. Mass spectroscopic analysis confirmed that ANP is rapidly cleaved at the first cysteine of the disulfide ring, whereas BNP is particularly stable to such cleavage. Other tissues (heart, aorta) failed to significantly degrade ANP or BNP, and therefore the kidney-specific degradation of ANP provides a mechanism for preferential regulation of kidney function by BNP independent of peripheral ANP concentration.",
keywords = "Atrial natriuretic peptide, B-type natriuretic peptide, Guanylyl cyclase-A, Neutral endopeptidase",
author = "I. Kishimoto and Hamra, {F. K.} and Garbers, {D. L.}",
year = "2001",
doi = "10.1139/cjpp-79-8-715",
language = "English (US)",
volume = "79",
pages = "715--722",
journal = "Canadian Journal of Physiology and Pharmacology",
issn = "0008-4212",
publisher = "National Research Council of Canada",
number = "8",

}

TY - JOUR

T1 - Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing

AU - Kishimoto, I.

AU - Hamra, F. K.

AU - Garbers, D. L.

PY - 2001

Y1 - 2001

N2 - Two natriuretic peptides, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), are found principally in the heart. In preliminary experiments with mouse kidney cells or slices, we found mouse BNP1-45 much more potent than ANP1-28 in causing elevations of cGMP (>50-fold). The guanylyl cyclase-A (GC-A) receptor has been suggested to represent the primary means by which both peptides signal. In cultured cells overexpressing GC-A, BNP and ANP were almost equivalent in potency, suggesting that a receptor unique for BNP exists in the kidney. However, in mice lacking the GC-A gene, neither BNP nor ANP significantly elevated cGMP in kidney slices. Phosphoramidon, a neutral endopeptidase inhibitor, shifted the apparent potency of ANP to values equivalent to that of BNP, suggesting these kidney cell/slices rapidly degrade ANP but not BNP. Mass spectroscopic analysis confirmed that ANP is rapidly cleaved at the first cysteine of the disulfide ring, whereas BNP is particularly stable to such cleavage. Other tissues (heart, aorta) failed to significantly degrade ANP or BNP, and therefore the kidney-specific degradation of ANP provides a mechanism for preferential regulation of kidney function by BNP independent of peripheral ANP concentration.

AB - Two natriuretic peptides, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), are found principally in the heart. In preliminary experiments with mouse kidney cells or slices, we found mouse BNP1-45 much more potent than ANP1-28 in causing elevations of cGMP (>50-fold). The guanylyl cyclase-A (GC-A) receptor has been suggested to represent the primary means by which both peptides signal. In cultured cells overexpressing GC-A, BNP and ANP were almost equivalent in potency, suggesting that a receptor unique for BNP exists in the kidney. However, in mice lacking the GC-A gene, neither BNP nor ANP significantly elevated cGMP in kidney slices. Phosphoramidon, a neutral endopeptidase inhibitor, shifted the apparent potency of ANP to values equivalent to that of BNP, suggesting these kidney cell/slices rapidly degrade ANP but not BNP. Mass spectroscopic analysis confirmed that ANP is rapidly cleaved at the first cysteine of the disulfide ring, whereas BNP is particularly stable to such cleavage. Other tissues (heart, aorta) failed to significantly degrade ANP or BNP, and therefore the kidney-specific degradation of ANP provides a mechanism for preferential regulation of kidney function by BNP independent of peripheral ANP concentration.

KW - Atrial natriuretic peptide

KW - B-type natriuretic peptide

KW - Guanylyl cyclase-A

KW - Neutral endopeptidase

UR - http://www.scopus.com/inward/record.url?scp=0034881382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034881382&partnerID=8YFLogxK

U2 - 10.1139/cjpp-79-8-715

DO - 10.1139/cjpp-79-8-715

M3 - Article

C2 - 11558680

AN - SCOPUS:0034881382

VL - 79

SP - 715

EP - 722

JO - Canadian Journal of Physiology and Pharmacology

JF - Canadian Journal of Physiology and Pharmacology

SN - 0008-4212

IS - 8

ER -